Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.47 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | KDM4D | Q6B0I6 | 3/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8122445 | 0.91 | TRPV1 (0.48) | TRPV1KDM4D | |
| SCHEMBL31040889 | 0.86 | TRPV1 (0.53) | TRPV1HSD17B2P2RX7 | |
| SCHEMBL20053921 | 0.86 | HSD17B2 (0.41) | TRPV1HSD17B2 | |
| SCHEMBL16814170 | 0.86 | AAK1 (0.41) | TRPV1HSD17B2 | |
| SCHEMBL5183286 | 0.84 | BDKRB1 (0.42) | TRPV1HSD17B2 | |
| SCHEMBL5183294 | 0.84 | BDKRB1 (0.42) | TRPV1HSD17B2 | |
| SCHEMBL29264385 | 0.84 | BRD4 (0.48) | TRPV1MAPK1 | |
| SCHEMBL7986840 | 0.84 | BRD4 (0.48) | TRPV1MAPK1 | |
| SCHEMBL24838475 | 0.83 | HSD17B2 (0.39) | TRPV1HSD17B2MAPK1KDM4D | |
| SCHEMBL24838468 | 0.83 | HSD17B2 (0.39) | TRPV1HSD17B2MAPK1KDM4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182436-A1 | SUBSTITUTED SULFONAMIDE-CHROMAN COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| WO-2022217248-A1 | SUBSTITUTED SULFONAMIDE-CHROMAN COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182436-A1 | SUBSTITUTED SULFONAMIDE-CHROMAN COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | ARSA, SNCA, F12 | TRPV1 1380/4885NTRK1 2791/4885HSD17B2 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.